Table 4.
Cardio-oncology in Poland
| Subject | Main characteristic | Activities for cardio-oncology |
|---|---|---|
| Centre of Postgraduate Medical Education | The central medical academic institution responsible for the preparation of programs and conducting and coordinating postgraduate medical education in Poland. |
“Oncology in Cardiology”—obligatory courses within the specialty program in cardiology Basics of Cardio-Oncology”—obligatory lectures during introductory courses in internal medicine and clinical oncology |
| Polish Cardiac Society (Polskie Towarzystwo Kardiologiczne, PTK) |
Part of the European Society of Cardiology (ESC) Polish members automatically become members of the ESC ESC guidelines are implemented in everyday clinical practice in Poland |
The 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity translated into Polish on the Polish Heart Journal after publication in the European Heart Journal Polish cardiologists are part of the ESC Council of Cardio-Oncology |
| Polish Lymphoma Research Group (PLRG) |
Thematic sections dedicated to specific clinical problems in lymphomas Each section meets semi-annually to discuss the achievements and define new purposes The cardio-oncology section meets regularly since 2011 |
Anthracycline-induced cardiotoxicity Early use of echocardiography in high risk DLBCL during R-CHOP / R-COMP chemotherapy Cardiovascular safety of pixantrone Cardiotoxicity of first and second generation BTK inhibitors |
| Polish National Oncology Network |
19 hospitals with oncology service Support of Polish Lung Cancer Group (PLCG) |
Since 2016 three annual nationwide Polish cardio-oncology congresses and 2 sessions during congresses of Polish Cardiac Society have been organized Ongoing program: Cardiology baseline assessment and evaluation during anticancer treatment in five selected types of cancer disease (1) breast cancer, (2) lung cancer, (3) ovarian cancer, (4) colorectal cancer, (5) prostate cancer |
ESC, European Society of Cardiology; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab-cyclophosphamide, doxorubicin hydrochloride, Oncovin (vincristine), prednisone; R-COMP, rituximab-cyclophosphamide, Oncovin, Myocet, prednisone; BTK, Bruton tyrosine kinase